With the development of medical research and treatment of colorectal cancer chemotherapy drugs have been developed, the clinical treatment of colorectal cancer chemotherapy drugs are mainly the following:
Treatment of cancer chemotherapy drugs (a) oxaliplatin uranium (uranium oxalate, Oxaliplatin, L-OHP)
Shun is the second consignment sales and calipers after the third class of anti-cancer drugs, anti-cancer spectrum is not identical. Preclinical studies have shown that lead exposure on colon cancer cell line oxaliplatin and cis lead resistance and other tumor cell lines significantly inhibited. I clinical trial showed that dose-limiting toxicity of oxaliplatin uranium insensitive to acute and cumulative transient peripheral neurotoxicity, a few months after cessation of treatment can be resumed. Oxaliplatin uranium to 130mg / time, every 3 weeks, or 85mg / when repeated every 2 weeks (intravenous infusion for 2 hours) when the recommended dose, no ototoxicity, renal toxicity, and dose-limiting toxicity of blood . H clinical trial of single-agent treatment in advanced colorectal cancer who received 5-Fu treatment or drug and had not received 5-Fu treatment objective response rate was 10% and 20%. Preclinical studies have shown that uranium and thymus slightly Xiao oxaliplatin synthase inhibitor, JI Fortunately or cards from the uranium, CTP-ll in combination have synergistic cytotoxicity.
Treatment of colorectal cancer chemotherapy drugs (b) Shannon irinotecan (Irinotecan, CTP-11)
Is an inhibitor of topoisomerase I, II clinical study showed that treatment of colon cancer without the effective rate of 20% of patients on 5-Fu resistance to the effective rate of 15% – 25%. CTP-ll the main side effects are mild neutropenia and diarrhea, severe degree of acid-based drugs wake up the degree of glucose and its metabolite SN-8 of the volume. CPT monotherapy for a 11 as second-line colorectal cancer treatment. According to the results of clinical trials E, Europe and the United States has approved the Joint 5 CPT-II in the u / LV as first-line treatment of colorectal cancer treatment.
Treatment of colorectal cancer chemotherapy drug (c) capecitabine (Capecitabine, Xelo towels, Xeloda)
Has the following characteristics: the first that oral amino acid fluorouracil slightly Anhui enzyme, can simulate the continuous infusion of 5-Fu and play a role in anti-tumor, tumor cells activated to enhance the efficacy and reduce toxicity. Of capecitabine for three different applications of a randomized clinical trial of H results show that the rates were 21%, 23% and 24%, and according to a longer time to disease progression CTTP), tolerability and therapeutic index, etc., to determine inter-Xie Kapei program gemcitabine monotherapy (treatment 2 weeks interval of 1 week) clinical trial as a dish using the best option. A total of 1207 cases of two multicenter randomized field trial of capecitabine alone compared with 5-Fu / A cool tetrahydrofolate CCF) as first-line treatment of metastatic colorectal cancer showed that capecitabine was effective 25.7% ,5-Fu / CF was 13.2% CP <0.0002), survival and disease progression was similar. Slight toxicity, mainly diarrhea and hand-foot syndrome. Specific programs are as follows: capecitabine 1250mg/Cmzed), 2 times a day [C total dose 2 500mg Cmz / ed)], orally for 14 days, rest 7 days, 21 days.
Treatment of colorectal cancer chemotherapy drug (IV) Tomudex CRaltitrexed)
Lin is the cha lag folate isomers of the same work, is a strong acid synthase chest selective inhibitor celecoxib. Zalcberg et al reported in a clinical study showed that E, 176 cases of untreated metastatic colorectal cancer patients received the drug treatment, the real effective rate of 26%, the median survival was 42 weeks. The main side effects were fatigue, diarrhea, leukopenia and asymptomatic transaminase elevation.